EVEREST MED (01952) announced that on October 28, 2025, the company entered into an agreement with Visara, Inc. (VISARA), a subsidiary of NewBridge Pharmaceuticals (formerly known as I-Mab, listed on the Nasdaq Global Market under the ticker "NBP"). Under the agreement, VISARA has irrevocably granted EVEREST MED an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and select Southeast Asian countries.

VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, demonstrating superior efficacy compared to first-generation treatments. It is expected to provide longer-lasting therapeutic benefits for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

Under the exclusive licensing agreement, EVEREST MED's payment obligations include: (i) an upfront payment of $7 million (approximately RMB 49.7 million) and reimbursement of up to RMB 24 million in self-funded expenses; (ii) potential development and sales milestone payments of up to $89 million (approximately RMB 632 million); and (iii) potential royalties based on net sales.

The board believes this strategic collaboration with VISARA will bring a highly differentiated and commercially attractive asset to EVEREST MED, enriching its late-stage product pipeline. Additionally, VIS-101 enables the company to expand into the competitive ophthalmology sector, which presents significant unmet medical needs.